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ABSTRACT:   The overall objective is to test the hypothesis that conjugated linoleic acid (CLA) has 
beneficial effects in Atlantic salmon through affecting lipid and fatty acid metabolism.   The specific 
aims of the present study were to determine the effects of CLA on some key pathways of fatty acid 
metabolism including fatty acid oxidation and highly unsaturated fatty acid (HUFA) synthesis.  Salmon 
smolts were fed diets containing two levels of fish oil (low, ~18% and high, ~34%) containing three 
levels of CLA (a 1:1 mixture of 9-cis,trans-11 and trans-10,cis-12 at 0, 1 and 2% of diet) for 3 months.  
The effects of dietary CLA on HUFA synthesis and β-oxidation were measured and the expression of 
key genes in the fatty acid oxidation and HUFA synthesis pathways, and potentially important 
transcription factors, peroxisome proliferators activated receptors (PPARs), determined in selected 
tissues. Liver HUFA synthesis and desaturase gene expression was increased by dietary CLA and 
decreased by high dietary oil content. Carnitine palmitoyltransferase-I (CPT-I) activity and gene 
expression were generally increased by CLA in muscle tissues although dietary oil content had 
relatively little effect. In general CPT-I activity or gene expression was not correlated with β-oxidation.  
Dietary CLA tended to increase PPARα and β gene expression in both liver and muscle tissues, and 
PPARγ in liver.  In summary, gene expression and activity of the fatty acid pathways were altered in 
response to dietary CLA and/or oil content, with data suggesting that PPARs are also regulated in 
response to CLA. Correlations were observed between dietary CLA, liver HUFA synthesis and 
desaturase gene expression, and liver PPARα expression, and also between dietary CLA, CPT-I 
expression and activity, and PPARα expression in muscle tissues. In conclusion, this study suggests 
that dietary CLA has effects on fatty acid metabolism in Atlantic salmon and on PPAR transcription 
factors. However, further work is required to assess the potential of CLA as a dietary supplement, and 
the role of PPARs in the regulation of lipid metabolism in fish.  
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CLA is a term used to describe conjugated isomers of linoleic acid (18:2n-6), the two main naturally 
occurring isomers being cis-9,trans-11 and trans-10,cis-12.  In mammals, dietary CLA has been shown 
to have a number of physiological effects and health benefits including anticarcinogenic and immune 
enhancing properties (1).  In addition, CLA has several beneficial effects on lipid metabolism in 
mammals, including altering body composition (2). Specifically, CLA decreased body fat and 
increased lean body mass in mice, rats and pigs (2). Decreased body fat has also been observed in 
human studies although the effect was much less than that observed with mice (3).  CLA is also known 
to decrease the activity and gene expression of mammalian stearoyl CoA Δ9 desaturase (4) and may 
also suppress Δ6 and Δ5 desaturase (5) and elongase (6).  
      There is accumulating evidence that some of the effects of CLA may be mediated through 
transcription factors such as peroxisome proliferator activated receptors (PPARs) or sterol regulatory 
element binding proteins (SREBPs). Specifically CLA isomers are ligands and activators of both 
PPARα (7) and PPARγ (8) that in mammals are, in turn, known to regulate the expression of genes of 
fatty acid oxidation and lipid deposition in liver and adipose tissue, respectively (9). Dietary CLA also 
influenced the expression of SREBPs in ob/ob mice (10). Both PPARs and SREBPs are involved in the 
control of fatty acid desaturation and elongation, with PPARα and SREBP-1 both affecting Δ6 and Δ5 
activities (11), and SREBP-1 also regulating elongase activities (12). Therefore, CLA via PPARs 
and/or SREBPs may affect lipid contents and fatty acid compositions in a variety of ways including 
selectivity in oxidation and deposition of specific fatty acids and modulation of fatty acid desaturation 
and elongation.  
       The overall objective is to test the hypothesis that CLA has beneficial effects in Atlantic salmon 
through affecting lipid and fatty acid metabolism. The specific aims of the present study were to 
determine the effects of CLA on some key pathways of fatty acid metabolism including fatty acid 
oxidation and highly unsaturated fatty acid (HUFA) synthesis via desaturation and elongation.  To this 
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end, salmon smolts were fed diets containing two levels of fish oil (low, ~18% and high, ~34%) 
containing three levels of CLA (a 1:1 mixture of the two main isomers present in nature, 9-cis,trans-11 
and trans-10,cis-12. at 0, 1 and 2% of diet) for 3 months.  The effects of dietary CLA on the expression 
of key genes of fatty acid oxidation and HUFA synthesis, and on the enzymic activities of the pathways 
were determined. In addition, the effect of CLA on the expression of potentially important transcription 
factors, PPARs, was determined in selected tissues. 
 
MATERIALS AND METHODS 
 
Diets and animals. Atlantic salmon smolts (S1/2) were obtained from a commercial salmonid farm 
(Howietoun Fish Farm, Sauchieburn, Scotland) in late October and transported to Stirling University, 
Institute of Aquaculture, Marine Environmental Research Laboratory, Machrihanish, Scotland.  The 
fish were maintained in stock tanks for three weeks at ambient water temperature of around 10-11 oC to 
acclimatize during which time the fish were fed standard salmon diet, before being randomly 
distributed between eighteen indoor, round, conical tanks of 1.5m3 volume (1.72m diameter).  The 
initial stocking density was 100 fish of average fish weight 87.5 ± 1.6 g per tank (5.8 kg/m3).  Water 
temperature was maintained at 12 oC (±1 oC) throughout the trial, with a light regime of 12L:12D.  Six 
experimental diets were fed to triplicate tanks for 3 months, with feed supplied to appetite manually. 
The experimental diets were formulated to satisfy the nutritional requirements of salmonid fish (13), 
and were formulated and manufactured by BioMar A/S, Brande, Denmark.  The trial had a 3 x 2 
factorial design with CLA added at three concentrations to diets with two oil contents (low and high).  
Thus diets were produced with 0, 1 and 2% CLA replacing standard Northern hemisphere fish oil in 
smolt feeds containing either 18 or 34% total lipid.  Diets were formulated to be isonitrogenous and so 
protein content was constant between diets of different oil content (Table 1).  Diets within the low or 
high oil groups were identical in formulation other than fatty acid composition with CLA (LUTA-
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CLATM 60, containing 60% CLA methyl esters as a 50:50 mixture of c9, t11 and t10, c12 isomers; 
BASF AG, Ludwigshafen, Germany) balanced by fish oil (capelin oil, Norsemeal Ltd., London, UK). 
The fatty acid compositions of the diets are presented in Table 2.  
       Sampling protocols.  At the termination of the trial, ten fish per dietary treatment (3-4/tank) were 
individually weighed, eviscerated and hepato- and viscero-somatic indeces determined. Samples of 
0.5g of liver, white and red muscle were rapidly dissected from six of the fish (two per tank) and 
immediately frozen in liquid nitrogen for RNA analyses. In addition, samples of 1-2g of liver, white 
and red muscle for biochemical analyses were collected from the same fish and immediately frozen in 
liquid nitrogen.  All samples were subsequently stored at –80 oC prior to analyses.   
       RNA extraction and real-time quantitative-polymerase chain reaction (rtqPCR). Total RNA was 
isolated from 100 - 500 µg (depending upon tissue) of pooled (2 fish) tissue by the standard TRIzol 
method (Invitrogen Ltd, Paisley, UK), and DNA removed using DNA-free™ DNase treatment 
(Ambion Inc., Austin, TX, USA).  Five µg of total RNA was reverse transcribed into cDNA using M-
MLV reverse transcriptase first strand cDNA synthesis kit (Promega UK, Southampton, UK). The PCR 
primers were designed according to the salmon cDNA sequences for ∆6 desaturase (accession no. 
AY458652), ∆5 desaturase (accession no: AF478472), CPT-I, PPARα (M.J. Leaver, personal 
communication), PPARβ (accession no: AJ416953) and PPARγ (accession no: AJ416951).  Primer 
sequences and PCR product sizes are given in Table 3. The linearised plasmid DNA containing the 
target sequence for each gene was quantified to generate a standard curve of known copy number.  
Amplification of cDNA samples and DNA standards was carried out using the SYBR Green PCR Kit 
(Applied Biosystems, Foster City, California, USA) with the following conditions: denaturation for 15 
min at 95 oC followed by 45 cycles of 15 s at 95 oC, 15 s at 56 oC and 30 s at 72 oC, followed by 
product melting to check purity of PCR product. Thermal cycling and fluorescence detection were 
conducted using the Rotor-Gene 3000 system (Corbett Research, Cambridge, UK).  Expression of 
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target genes was normalised using Quant-iTTM High Sensitivity DNA Assay kit containing PicoGreen 
reagent, (Molecular Probes, Rijinsburgerweg, The Netherlands) using a modified version of the 
manufacturers protocol (14). All reactions were carried out in duplicate and a linear standard curve was 
drawn, plotting the average absorbance values obtained for the Quant-iTTM DNA values against the 
standard DNA concentration, with the concentration of total cDNA calculated from the linear equation.  
       Fatty acid desaturation and elongation (HUFA synthesis) in liver microsomes.  Portions of frozen 
liver were homogenised to 10% (w/v) in 0.25 M sucrose in 40 mM phosphate buffer pH 7.4 containing 
1 mM EDTA, 0.15 M KCl, 40 mM KF and 1 mM N-acetyl cysteine. The homogenate was centrifuged 
at 25 000 g for 15 min at 4 oC, the floating fat layer removed by aspiration and the remaining 
supernatant centrifuged at 105 000 g for 60 min at 4 oC.  The floating fat layer was aspirated and the 
supernatant decanted.  The pelleted microsomal fraction was resuspended in 1 ml of sucrose buffer and 
50 µl taken for protein determination according to Lowry et al. (15) after incubation with 0.45 ml of 
0.25% (w/v) SDS/1M NaOH for 45 min at 60oC.  The assay mixture, in sucrose buffer pH 7.4, 
contained 5 mM MgCl2, 1.5 mM glutathione, 0.5 mM nicotinamide, 1 mM NADH, 100 µM coenzyme 
A, and 5 mM ATP in a total volume of 0.75 ml. Fifty µl of [1-14C]18:3n-3 (0.25 µCi, 5 µM final 
concentration), as a fatty acid-free (FAF) BSA complex, was added and the reaction initiated by the 
addition of 200 µl of microsomes.  Incubation continued for 1 h at 20 oC and the reaction was stopped 
by the addition of 5 ml of chloroform/methanol (2:1, v/v) containing 0.01% BHT, and total lipid 
extracted, transmethylated and FAME prepared as described previously (16). FAME were separated by 
argentation TLC, visualized by autoradiography and radioactivity determined by scintillation counting 
as described previously (17).  
       Assay of carnitine palmitoyltransferase I (CPT-I) and fatty acyl β-oxidation in tissue homogenates.  
Liver, red and white muscle were weighed, diced and homogenised to 20% (w/v) in 0.25 M sucrose in 
10 mM N-2-hydroxyethylpiperazine-N´-2-ethanesulfonic acid (HEPES) buffer and 1 mM EDTA, pH 
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7.4. The homogenates were centrifuged at 1880 x g for 10 min at 4˚C, the floating fat layer aspirated 
and the post-nuclear fractions collected, 50 µl taken for protein determination as above, and portions 
used immediately for determination of enzyme activities. CPT-I activity was estimated by determining 
the production of palmitoyl[3H]carnitine from palmitoyl CoA and [3H]carnitine essentially as described 
by Saggerson and Carpenter (18).  Fatty acyl β-oxidation was estimated by determining radioactivity in 
acid soluble products derived from the oxidation of [1-14C]palmitoyl-CoA as described by Torstensen 
et al. (19).   
       Materials. [1-14C] Palmitoyl CoA (50-55 mCi/mmol) and [methyl-3H] L-carnitine hydrochloride 
(60-86 Ci/mmol) were obtained from GE Healthcare Bio-Sciences (Little Chalfont, Bucks, U.K.), and 
[1-14C]18:3n-3 (50-55 mCi/mmol) was obtained from NEN (Perkin Elmer LAS (UK) Ltd., 
Beaconsfield, U.K.). BHT, carnitine, FAF-BSA, HEPES, palmitoyl-CoA, silver nitrate and TriReagent 
were obtained from Sigma Chemical Co. (Poole, U.K.). TLC (20 cm x 20 cm x 0.25 mm) plates, 
precoated with silica gel 60 (without fluorescent indicator) were obtained from Merck (Darmstadt, 
Germany).  All solvents were HPLC grade and were obtained from Fisher Scientific UK, 
Loughborough, England. 
      Statistical  analysis.  All data are presented as means ± SD (n value as stated). Percentage data and 
data which were identified as non-homogeneous (Bartlett’s test) were subjected to arcsine 
transformation before analysis.  The effects of dietary CLA and oil content were determined by two-
way ANOVA with Bonferroni post-tests to determine significance of differences due to CLA. 
Differences were regarded as significant when P < 0.05 (20). 
 
RESULTS 
Diet composition, growth and biometry.  Inclusion of CLA in the low oil diets resulted in levels of total 
CLA of 5.9% and 9.5% of total fatty acids at the 1 and 2% inclusion levels, respectively (Table 2). 
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Obviously, in the high oil diets, inclusion of CLA at 1 and 2% resulted in lower levels of total CLA, at 
3.3% and 5.8% of total fatty acids, respectively.  The levels of CLA in relative terms were identical in 
the L1 and H2 diets with an overall rank order for CLA content of L2 > L1 = H2 > H1 > L0/H0.  There 
were no effects of diet on growth parameters, with no significant effects of CLA or oil content on final 
weights or specific growth rate (SGR) (Table 4).  
      Tissue enzyme activities.  HUFA synthesis in liver microsomes, as measured by the recovery of 
radioactivity in the summed Δ6 and Δ5 desaturated products (18:4, 20:4, 20:5 and 22:5) of [1-
14C]18:3n-3, was significantly affected by both dietary oil content and CLA as determined by two-way 
ANOVA (Table 5). However there was significant interaction between the variables, as activity was 
significantly higher in fish fed 2% CLA compared to fish fed FO alone at the low oil level whereas the 
opposite trend was observed at the high oil level (Fig.1).  HUFA synthesis activity in liver was 
significantly lower in fish fed the high oil diet (Table 5, Fig.1).   
      Dietary CLA did not significantly increase β-oxidation activity in white muscle irrespective of 
dietary oil content (Table 5, Fig.2).  There was a trend suggesting CLA may also increase β-oxidation 
in red muscle in fish fed high dietary oil, but the high variation made this non-significant.   Liver β-
oxidation was significantly lower in fish fed the high oil diet, but dietary CLA had no effect on β-
oxidation in liver (Table 5, Fig.2).  Dietary oil content had no effect on β-oxidation activities in either 
muscle tissue.  
     CPT-I activity was significantly increased by dietary CLA in white muscle, and also in red muscle, 
particularly in fish fed the high oil diets (Table 5, Fig.3).  CPT-I activity in white muscle was also 
significantly increased by high dietary oil. In contrast, hepatic CPT-I activity was unaffected by dietary 
oil content, but there was a trend for it to be decreased by dietary CLA in the low oil group (Table 5, 
Fig.3). 
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      Tissue enzyme expression.  The expression of fatty acid Δ6 and Δ5 desaturases in liver was 
significantly affected by both dietary CLA and oil content (Table 5).  Specifically, expression of both 
desaturases was increased by dietary CLA and reduced by high dietary oil content (Fig. 4). CPT-I 
expression in all three tissues, red and white muscle, and liver, was significantly increased by dietary 
CLA (Table 5, Fig.5).  However, CPT-I expression was not affected by dietary oil content in either 
muscle tissue although it was increased in liver tissue, at least in fish also being fed CLA (Table 5, 
Fig.5).  
      Tissue PPAR expression.  The expression of all PPAR subtypes was significantly affected by both 
dietary CLA and oil content (Table 5). PPARα expression was increased by dietary CLA in liver and, 
to a lesser extent, white muscle (Fig.6).  In red muscle, there was a strong interaction between dietary 
CLA and oil content such that CLA increased expression at low oil contents, but the opposite at high 
dietary oil content.  High oil content may have induced increased expression of PPARα in red muscle 
although the interaction also made this difficult to interpret.  PPARβ expression in the muscle tissues 
was similar to that for PPARα in these tissues.  Thus the expression of PPARβ was increased by 
dietary CLA in white muscle whereas there was a significant interaction between CLA and dietary oil 
in red muscle, which made the effects of CLA difficult to interpret (Table 5). However, PPARβ 
expression was increased by high dietary oil, but dietary CLA decreased PPARβ expression in red 
muscle in fish fed high dietary oil (Fig.7). The expression of PPARβ in liver was greatest in fish fed 
1% CLA (Table 5, Fig. 7). Expression of PPARγ in liver was significantly increased by dietary CLA, 
but dietary oil content had no significant effect (Table 5, Fig.8). PPARγ expression in muscle tissues 
was too low to be reliably determined.  
     
DISCUSSION 
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CLA has the capacity to exert both agonistic and antagonistic effects on a wide variety of lipid 
metabolic factors. These effects are dependent upon the pattern of lipid metabolism, which itself varies 
with species, tissue type, and age, and dietary factors including lipid content, CLA isomer composition 
and duration of supplementation. Thus, it is difficult to define a specific biochemical mechanism of 
action.  However, the view that CLA can affect lipid accumulation both by decreasing de novo fatty 
acid synthesis and increasing oxidation is well established, at least in mammals.  For example, CLA 
inhibits fatty acid synthetase activity in rat liver (21), and suppresses TAG accumulation and increases 
fatty acid oxidation in 3T3-L1 adipocytes (22). It is hypothesised that CLA exerts such effects on lipid 
metabolism at the transcriptional level by altering gene expression of key regulatory proteins and 
enzymes mediated, in part, by PPARs.  However, it was unclear whether CLA have the ability to alter 
lipid metabolism in fish in a manner similar to that of mammalian models (23).   
In the present study, salmon fed CLA exhibited increased expression of Δ5 and Δ6 fatty acid 
desaturases in liver; particularly evident in the low oil diet, which displayed around a 2-fold increase in 
expression of Δ5 and Δ6 at 2% inclusion of CLA.  This was at least partly reflected in HUFA synthesis 
activity, which increased in fish fed 2% CLA at the low dietary oil content.   Analogously, Δ5 and Δ6 
fatty acid desaturase expression was increased in mice fed CLA (24), whilst the amount of the HUFA, 
EPA and DHA, increased in hybrid striped bass Morone chrysops, saxatilis in response to dietary CLA 
(25). One explanation may be that transcription factors equivalent to mammalian PPARα and SREBP-
1c are directly involved in regulating Δ6 and Δ5 desaturases in fish via a feedback mechanism.   A 
similar mechanism for the regulation of desaturase gene expression has been proposed in mammals 
whereby Δ6 desaturase gene expression is partly regulated by PPARα (26). Thus, it was shown that 
ligand activation of PPARα via peroxisome proliferators may result in upregulation of Δ5 and Δ6 
desaturase, whilst high PUFA feeding down regulated these genes in a SREBP-1-dependent 
mechanism (11). In salmon liver, CLA feeding was associated with increases in Δ5 and Δ6 desaturase 
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expression and HUFA synthesis in low oil treatments, which might be indicative of a role for ligand 
activation of PPARα by CLA. In contrast, in high oil diets, Δ5 and Δ6 expression and HUFA synthesis 
was repressed, even in the presence of similar amounts of CLA, possibly indicating a role for SREBP-1 
proteins. Interestingly, CLA feeding also increased the levels of PPARα, providing some further 
support for this mechanism of regulation in salmon liver. Previously however, we reported that dietary 
CLA had no significant effect on either liver or flesh (muscle) fatty acid compositions in salmon, thus it 
appears that the increased fatty acid desaturase expression and HUFA synthesis activity does not have a 
major physiological consequence in terms of gross fatty acid compositions (16).  That alterations in 
desaturase gene expression and HUFA synthesis activity in liver can have relatively little effect on 
tissue fatty acid compositions has been demonstrated previously in several trials in which salmon have 
been fed vegetable oils (see 27). The data from the present trial also show a correlation between 
desaturase expression and HUFA synthesis activity, and dietary oil content, with diets containing high 
oil conferring significantly lower levels of desaturase expression and HUFA synthesis activity 
compared to low oil diets. In addition to effects on HUFA synthesis, it is well established that there is a 
reduction in fatty acid synthesis (lipogenesis) as a result of high dietary oil levels, as demonstrated in 
Atlantic salmon and other fish species (28). 
Beta-oxidation is the principal means of fatty acid catabolism in vertebrates and the basic 
mechanism of the pathway, and possibly regulation, appear to be highly conserved in mammals and 
fish (29).   Recently, it has been suggested that CLA can increase mitochondrial β-oxidation in a 
variety of tissues in rats via an increase in CPT-I (30). Moreover, evidence of increased fatty acid 
oxidation after CLA supplementation is presented in similar studies, which indicated CLA increased 
gene expression and activity of CPT-I in mouse liver (31).  However, in the present trial, β-oxidation 
capacity was not significantly affected in red or white muscle tissue of fish fed dietary CLA, despite 
mitochondrial β-oxidation predominating over peroxisomal β-oxidation in salmon red and white 
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muscle (32).  In contrast, CLA significantly increased both CPT-I expression and activity in these 
tissues. The reasons for the lack of association of CPT-I with β-oxidation are unclear. Increased CPT-I 
activities in liver and red muscle of hamsters fed CLA was not correlated with increased fatty acid 
oxidation (33). The authors speculated this may have been due to increased sensitivity of CPT-I to 
malonyl-CoA in animals fed CLA (33).  As in mammals, malonyl-CoA is an inhibitor of CPT-I in 
Atlantic salmon, but it is not known if CLA can affect its potency (34). There are few data in fish 
species to compare the present data with.  However, dietary lipid level did not alter β-oxidation activity 
in the muscle of haddock Melanogrammus aeglefinus L. fed graded levels of oil (29).  In the present 
study, dietary oil content had no major effect on β-oxidation activity or CPT-I mRNA levels in either 
red or white muscle, or CPT-I activity in red muscle, although CPT-I activity was increased by dietary 
oil content in white muscle.    
Previous studies in rodents showed that CPT-I mRNA level was elevated in liver in response to 
dietary CLA (31). In the present study and similar to results in muscle, CPT-I gene expression was 
found to be upregulated in salmon liver in response to dietary CLA, although this was not accompanied 
by increased CPT-I or β-oxidation activities.  Furthermore, CPT-I expression was higher in salmon 
liver in fish fed the high oil diet when fed in combination with CLA.  Consistent with this it appeared 
that in fish fed CLA, CPT-I activity was lower in fish fed the low oil diet compared with fish fed the 
high oil.  However, these effects on CPT-I expression and activity in liver were not reflected in β-
oxidation activity, which surprisingly was reduced in fish fed the high oil diet. These results seem 
contradictory considering that the in vivo rate of fatty acid oxidation should be associated with in vitro 
CPT-I activity (35). Nevertheless, studies determining changes in energy metabolism in hamsters fed 
CLA also found disparities between the activity of CPT-I and lipid oxidation in the liver (33).  
Pertinent to this lack of correlation between CPT-I expression and activity and β-oxidation activity in 
liver is the fact that, with Atlantic salmon of similar age and size, catabolism of fatty acids in liver was 
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reported to be principally due to peroxisomal, rather than mitochondrial, β-oxidation (32).  
Consequently, CPT-I may not have a prominent role as a regulatory element of fatty acid oxidation in 
salmon smolt liver, considering it is primarily involved in mitochondrial metabolism (36). This may be 
relevant in the present study as it clearly provides a mechanism whereby changes in CPT-I expression 
and/or activity can be unrelated to β-oxidation activity in liver. This remains the case even considering 
that, in the present study, only total β-oxidation, combining mitochondrial and peroxisomal β-
oxidation, was determined.   Clearly though it also suggests that peroxisomal β-oxidation in salmon 
liver was unaffected by dietary CLA, and actually decreased by high dietary oil. In comparison, graded 
levels of dietary lipid showed no significant differences in β-oxidation activity in liver of haddock (29). 
There is consolidating evidence that lipid homeostasis is, at least in part, modulated through the 
PPAR transcription factors in mammals.  Recent studies suggest that CLA could mediate this activation 
by acting as high-affinity ligands for a number of PPAR isotypes, particularly PPARα (7).  PPARα is 
intimately involved in the regulation of genes involved in mitochondrial fatty acid oxidative processes 
in mammals (37), whereas PPARγ is primarily involved in lipid deposition via preadipocyte 
differentiation and lipogenesis (38).  Very recent work has elucidated that marine fish also share 
homologous gene sequences, with similar phylogenetic characteristics, to the mammalian PPAR 
counterparts, possibly also suggesting similar molecular roles (39,40). However, Atlantic salmon may 
possibly contain up to five PPAR genes, as opposed to three in mammals, and therefore the precise role 
of piscine PPARs have not been conclusively defined (40).  
The effects of CLA on mammalian PPAR gene expression are ambiguous and seem to be 
dependant partly on species, partly on tissue type, and partly on CLA isomer. The majority of studies 
describe a decrease in PPARγ mRNA in isolated adipocytes, or in adipose tissue from mice treated with 
t-10, c-12 CLA or a 1:1 mixture of the two predominant CLA isomers (41,42). Conversely, CLA has 
also been reported to increase expression of PPARγ in liver of mice, and in white adipose tissue in rats 
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(43,44).  Trans-10 c-12 CLA downregulated PPARα in mice (45), however there was no change in 
PPARα expression in liver of hamsters fed diets containing t-10 c-12 or c-9 t-11 CLA (46). In the 
present study, there was a trend for PPARα expression to be increased by dietary CLA in liver, red and 
white muscle of fish fed the low oil diets. In addition, upregulation of PPARα in response to dietary 
CLA was also observed in white muscle and liver in fish fed the high oil diets.  As mentioned above, 
activation of PPARα (via peroxisome proliferators) can induce β-oxidation through upregulation of 
key enzymes such as CPT-I in mammals (37).  The data in the present trial suggest that PPARα may 
also be implicated in the action of CLA. In general CLA increased the levels of both CPT-I mRNA and 
PPARα and in some cases PPARβ mRNA. The exceptions to this were PPARα and PPARβ expression 
in red muscle from fish fed high oil, which tended to decrease with dietary CLA inclusion, and at high 
CLA inclusion liver PPARβ was decreased. It has been shown in PPARα-knockout mice that the 
effects of CLA on body fat distribution and mitochondrial lipid catabolism genes are not mediated by 
PPARα, but that the peroxisomal β-oxidation gene acyl CoA oxidase is regulated by a PPARα-
dependent mechanism (47).  Acyl CoA oxidase shows high activity in salmon liver, but much lower 
activity in red muscle and very low activity in white muscle (34).  Thus, it is possible that effects on 
mitochondrial lipid catabolic genes such as CPT-I could be mediated through PPARβ subtypes. 
However, PPARα expression exceeds that of PPARβ by an order of magnitude in muscle tissues 
suggesting PPARα would have the predominant regulatory role.  Of course, it is not the absolute 
amount of PPAR that is important for target gene activation, but rather the binding of activating ligand.  
           Of the tissues investigated in salmon, PPARγ expression was only detected in liver.  However, 
in agreement with work carried out on mice (43), PPARγ mRNA levels increased in liver of salmon fed 
CLA, and CLA have been reported to cause ‘fatty liver’ in mice (43).  However, fish PPARγ does not 
share the same ligand activation profile as in mammals (40). Fish PPARγ does not respond to fatty 
acids and has specific amino acid differences compared to the mammalian form which explains lack of 
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activation, suggesting that is unlikely, despite increases in liver, that CLA would mediate its effects 
through this transcription factor.  Indeed, neither liver size nor lipid content was increased in salmon 
fed CLA (16).  
In summary, gene expression and activity of various lipid metabolic factors were altered in 
response to graded levels of CLA and/or dietary oil content in Atlantic salmon smolts. Specifically, 
some association was observed between dietary CLA, liver HUFA synthesis and desaturase gene 
expression, and liver PPARα expression although this varied with dietary oil content. In addition, some 
association between dietary CLA, CPT-I expression and activity, and PPARα expression was observed 
in muscle tissues. However, the magnitude of the changes in fatty acid metabolism observed were not 
sufficient to bring about major changes in the whole body lipid and fatty acid composition of the fish 
(16). In conclusion, this study has presented evidence that dietary CLA have effects on fatty acid 
metabolism in Atlantic salmon, but that there is little evidence of a direct mechanism involving PPAR 
transcription factors. However, considering the importance of dietary lipid in aquaculture, further work 
is required to assess the potential of CLA as a dietary supplement, and the role of PPARs in the 
regulation of lipid metabolism in fish.  
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Legends to Figures 
 
FIG. 1. Effects of dietary oil content and conjugated linoleic acid (CLA) on highly unsaturated fatty 
acid (HUFA) synthesis in the liver microsomes. Specific activities are presented as means ± SD (n = 3) 
and were determined as described in Materials and Methods.  
 
FIG. 2. Effects of dietary oil content and conjugated linoleic acid (CLA) on total β-oxidation activities 
in tissue homogenates of red and white muscle, and liver. Specific activities are presented as means ± 
SD (n = 3) and were determined as described in Materials and Methods.  
 
FIG. 3. Effects of dietary oil content and conjugated linoleic acid (CLA) on carnitine 
palmitoyltransferase I (CPT-I) activities in tissue homogenates of red and white muscle, and liver. 
Specific activities are presented as means ± SD (n = 3) and were determined as described in Materials 
and Methods.  
 
FIG. 4. Effects of dietary oil content and conjugated linoleic acid (CLA) on the expression of Δ6 and 
Δ5 fatty acid desaturase genes in liver.  Genes were determined by rtqPCR and normalised relative to 
total RNA, determined by fluorescent assay, as described in Materials and Methods.  Results are 
presented as means and SD (n = 3).  
 
FIG. 5. Effects of dietary oil content and conjugated linoleic acid (CLA) on the expression of carnitine 
palmitoyltransferase-I (CPT-I) in the liver, red and white muscle. Genes were determined by rtqPCR 
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and normalised relative to total RNA, determined by fluorescent assay, as described in Materials and 
Methods.  Results are presented as means and SD (n = 3).  
 
FIG. 6. Effects of dietary oil content and conjugated linoleic acid (CLA) on the expression of PPARα 
in the liver, red and white muscle, and adipose tissue. Genes were determined by rtqPCR and 
normalised relative to total RNA, determined by fluorescent assay, as described in Materials and 
Methods.  Results are presented as means and SD (n = 3).  
 
FIG. 7. Effects of dietary oil content and conjugated linoleic acid (CLA) on the expression of PPARβ 
in the liver, red and white muscle, and adipose tissue. Genes were determined by rtqPCR and 
normalised relative to total RNA, determined by fluorescent assay, as described in Materials and 
Methods.  
 
FIG.8. Effects of dietary oil content and conjugated linoleic acid (CLA) on the expression of PPARγ in 
liver. Gene expression was determined by rtqPCR and normalised relative to total RNA, determined by 
fluorescent assay, as described in Materials and Methods.  Results are presented as means and SD (n = 
3).  
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Table 1
Formulations (percentage of dry ingredients) and proximate compositions (percentage 
of total diet) of experimental diets
Fishmeal
Sunflower meal
Corn Gluten
Legume seeds
Cereal grains
Micronutrients
Fish oil
CLA
Moisture 8.0 ± 0.3 8.7 ± 0.1 8.9 ± 0.1 3.1 ± 0.1 4.2 ± 0.4 4.4 ± 0.1
Lipid 18.2 ± 0.3 17.4 ± 0.1 16.4 ± 0.5 33.2 ± 0.6 32.4 ± 1.2 32.6 ± 1.6
Protein 44.8 ± 0.1 44.8 ± 0.2 45.8 ± 0.5 47.0 ± 0.3 47.0 ± 0.3 47.1 ± 1.3
Ash 7.8 ± 0.1 7.8 ± 0.1 7.9 ± 0.1 8.2 ± 0.1 8.1 ± 0.0 8.0 ± 0.2
Results for proximate compositions are means ± S.D. (n=3). Micronutrients, incl. essential amino  
acids (methionine and lysine), vitamins, minerals and astaxanthin (Carophyll pink®), Biomar A/S, 
Brande, Denmark.  H0, H1 and H2, diets containing fish oil at 34% and supplemented with 0, 1 and 
2% CLA; L0, L1 and L2, diets containing fish oil at 17% and supplemented with 0, 1 and 2% CLA. 
L0 H2L1 L2 H0 H1
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Table 2 
(CLA) fed to Atlantic salmon (Salmo salar). 
Total saturated 30.7 ± 1.0 ab 28.6 ± 1.1 b 28.9 ± 1.4 b 31.9 ± 0.4 a 30.6 ± 0.7 ab 31.0 ± 0.8 ab
Total monoenes 30.1 ± 0.7 30.0 ± 0.7 31.0 ± 0.9 29.8 ± 0.6 29.3 ± 0.4 30.2 ± 0.5
18:2n-6 6.4 ± 0.2 b 6.6 ± 0.1 ab 6.8 ± 0.2 a 3.1 ± 0.1 c 3.3 ± 0.0 c 3.2 ± 0.0 c
20:4n-6 0.9 ± 0.0 ab 0.8 ± 0.0 bc 0.7 ± 0.0 c 1.0 ± 0.1 a 0.9 ± 0.0 ab 0.8 ± 0.0 bc
Total n-6 PUFA1 8.4 ± 0.1 a 8.2 ± 0.5 a 8.2 ± 0.6 a 5.1 ± 0.1 b 5.0 ± 0.2 b 4.8 ± 0.5 b
18:3n-3 1.2 ± 0.0 a 1.1 ± 0.0 ab 1.0 ± 0.0 a 1.2 ± 0.0 a 1.2 ± 0.0 a 1.1 ± 0.0 ab
18:4n-3 2.5 ± 0.1 b 2.1 ± 0.0 d 1.8 ± 0.0 e 2.7 ± 0.0 a 2.6 ± 0.0 ab 2.3 ± 0.0 c
20:4n-3 0.7 ± 0.0 ab 0.6 ± 0.0 bc 0.5 ± 0.0 c 0.8 ± 0.0 a 0.8 ± 0.0 a 0.7 ± 0.0 ab
20:5n-3 11.8 ± 0.7 b 10.2 ± 0.2 c 8.4 ± 0.5 d 13.6 ± 0.1 a 13.0 ± 0.1 a 11.5 ± 0.1 b
22:5n-3 1.8 ± 0.1 b 1.6 ± 0.0 c 1.3 ± 0.1 d 2.0 ± 0.0 a 1.9 ± 0.0 a 1.7 ± 0.0 bc
22:6n-3 12.7 ± 0.9 a 11.5 ± 0.5 b 9.5 ± 0.1 c 12.9 ± 0.0 a 12.4 ± 0.2 a 10.9 ± 0.1 b
Total n-3 PUFA2 30.8 ± 1.8 a 27.3 ± 0.8 b 22.6 ± 0.7 c 33.2 ± 0.3 a 31.8 ± 0.4 a 28.2 ± 0.2 b
CLA (9c,11t) 0.0 ± 0.0 d 2.9 ± 0.5 b 4.8 ± 1.6 a 0.0 ± 0.0 d 1.6 ± 0.2 c 2.9 ± 0.7 b
CLA (10t,12c) 0.0 ± 0.0 d 3.0 ± 0.4 b 4.6 ± 1.7 a 0.0 ± 0.0 d 1.7 ± 0.4 c 2.9 ± 0.8 b
Total CLA 0.0 ± 0.0 d 5.9 ± 0.5 b 9.4 ± 1.5 a 0.0 ± 0.0 d 3.3 ± 0.4 c 5.8 ± 0.7 b
Total PUFA 39.2 ± 1.7 41.5 ± 1.8 40.2 ± 2.4 38.3 ± 0.2 40.13 ± 1.1 38.8 ± 1.3
Values are means ± SD of 3 samples. Significance of differences between mean values were determined by one-way
ANOVA followed, where appropriate, by Tukey's multiple comparison test as described in the Materials and methods.
Values within a row with a different superscript letter are significantly different (P < 0.05). 1, totals include 18:3n-6, 
20:2n-6 and 22:5n-6 present in some samples at up to 0.4%; 2, totals contain 20:3n-3 present at up to 0.2%.  H0, H1 
and H2, diets containing fish oil at 34% and supplemented with 0, 1 and 2% CLA; L0, L1 and L2, diets containing 
fish oil at 17% and supplemented with 0, 1 and 2% CLA. PUFA, polyunsaturated fatty acids.
Fatty acid composition (percentage of weight) of experimental diets containing conjugated linoleic acid 
L0 L1 L2 H0 H1 H2
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Table 3
Forward (sense) and reverse (antisense) primers used for real-time quantitative RT-PCR
Gene PCR product length Forward primer Reverse primer
Δ5 Desaturase 192 5’-GTGAATGGGGATCCATAGCA-3’ 5’-AAACGAACGGACAACCAGA-3’.
Δ6 Desaturase 181 5'-CCCCAGACGTTTGTGTCAG-3’ 5’-CCTGGATTGTTGCTTTGGAT-3’
CPT-1 161 5'-GAGAGAGCTGCGACTGAAAC-3' 5'-GACAGCACCTCTTTGAGGAA-3'
PPARα 204 5'-ATCTTCCACTGCTGCCAGTGC-3' 5'-GATGAAGCCCGATCCGTAGGCCACCAGG-3'
PPARβ1 517 5'-TACCGCTGCCAGTGCACCACGGTG-3' 5'-TTCTGGACCAAGCTGGCGTTCTCA-3'
PPARγ 266 5'-TATCTCCCCTCTCTAGAGTA-3' 5'-AGGGCTTATCGTTTACTGAACCTTGATACACGC-3'
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Table 4
Final weights of Atlantic salmon (Salmo salar)
fed diets containing conjugated linoleic acid (CLA)
Diet
L0 87.8 ± 1.5 256.3 ± 18.7
L1 87.4 ± 0.5 236.3 ± 17.6
L2 87.9 ± 2.2 236.7 ± 18.4
H0 85.5 ± 1.5 245.4 ± 12.1
H1 89.3 ± 0.9 260.8 ± 13.1
H2 86.9 ± 0.6 260.4 ± 5.4
Data are presented as means ± SD, n = 100 and 10 for 
initial and final weights); SGR, specific growth rate 
(%/day) = 100 x [(ln weightfinal - ln weightinitial ) x days-1]; 
L0, L1 and L2, low lipid diets with 0, 1 and 2% CLA; 
H0, H1 and H2, high lipid diets with 0, 1 and 2% CLA. 
There were no significant differences between dietary 
treatments as determined by two-way ANOVA.
Initial Weight (g) Final Weights (g) SGR
1.29
1.31
1.34
1.31
1.21
1.21
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Table 5
Significance (P values) of effects of dietary conjugated 
linoleic acid (CLA) and oil content (Oil), and their 
interaction (Interact.) as determined by two-way ANOVA 
as described in the Methods section.
CLA Oil Interact.
Liver
HUFA synthesis activity < 0.0001 < 0.0001 < 0.0001
Δ6 desaturase expression 0.0009 <0.0001 0.0156
Δ5 desaturase expression 0.0031 0.0009 0.5247
β-oxidation activity 0.2757 0.0136 0.5943
CPT-I activity 0.8506 0.5573 0.8676
CPT-I expression 0.0027 0.001 0.0483
PPARα expression 0.0001 0.0347 0.1144
PPARβ expression 0.0004 0.0445 0.1649
PPARγ expression 0.0449 0.2061 0.237
Red muscle
β-oxidation activity 0.8133 0.3457 0.5257
CPT-I activity 0.0355 0.1511 0.4857
CPT-I expression 0.0022 0.7695 0.3469
PPARα expression 0.2603 0.0172 0.0034
PPARβ expression 0.1182 <0.0001 0.046
White muscle
β-oxidation activity 0.0795 0.1473 0.8623
CPT-I activity 0.0075 0.0001 0.1409
CPT-I expression 0.0077 0.7394 0.2716
PPARα expression 0.0292 0.0518 0.0836
PPARβ expression 0.0032 0.0006 0.0822
 CPT-I, carnitine palmitoyltransferase-I; HUFA, highly 
unsaturated fatty acids; PPAR, peroxisome proliferator 
activated receptor; PUFA, polyunsaturated fatty acid.
P Value
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